Sen-Jam Pharmaceutical, Inc., a clinical-stage biopharma developing affordable therapeutics for inflammation-driven conditions, has announced a strategic partnership with Opus8, Inc., a premier capital advisory and investor network led by CEO S. Tien Wong.
Through the collaboration, Sen-Jam will tap into the CONNECTpreneur Investor Network, which includes more than 4,000 accredited investors, family offices, and high-net-worth individuals. The agreement will provide Sen-Jam with exclusive investor meetings, curated introductions, and the opportunity to present at CONNECTpreneur Forums — with the goal of accelerating capital formation and expanding its strategic investor base.
Building Investor Momentum
The engagement launches this fall with an investor sprint that includes an East Coast reception and virtual events. A second phase will expand outreach to New York, Silicon Valley, and the J.P. Morgan Healthcare Conference in San Francisco — one of the industry’s most influential investor gatherings.
“This partnership with Opus8 is a major milestone for Sen-Jam,” said Jim Iversen, CEO of Sen-Jam. “With Opus8’s proven network and expertise, we will broaden our reach and advance our mission to bring disruptive anti-inflammatory therapeutics to patients worldwide.”
S. Tien Wong, CEO of Opus8, added: “Sen-Jam is at the forefront of developing innovative solutions for global health challenges. We are proud to support their journey by connecting them with the right investors to accelerate growth and impact.”
Advancing an Inflammation-Focused Pipeline
Sen-Jam’s pipeline spans 11 assets in development, supported by more than 60 patents worldwide. Its leading candidates include:
- SJP-001 – entering Phase 2 clinical trials for alcohol-induced inflammation
- SJP-002C – a novel therapy for upper respiratory infections, which recently completed a Phase 2 study with Duke University, and is now being evaluated for potential use in metabolic/obesity/MASH indications
The company leverages its proprietary PAIR (Pleiotropic Anti-Inflammatory Regulators) platform alongside AI-driven data analysis to accelerate drug discovery, optimize clinical insights, and sharpen its ability to deliver first-in-class solutions.
Why It Matters
For emerging biopharma companies, access to capital is often the biggest determinant of how quickly innovation can reach patients. By joining forces with Opus8 and its expansive investor network, Sen-Jam is positioning itself to move faster — both in advancing its clinical pipeline and in scaling its impact.
As more investors seek opportunities at the intersection of affordability, accessibility, and breakthrough science, partnerships like this highlight how biotech innovation and strategic capital formation go hand in hand.
